ATE413389T1 - Chinazolinderivate - Google Patents

Chinazolinderivate

Info

Publication number
ATE413389T1
ATE413389T1 AT05701999T AT05701999T ATE413389T1 AT E413389 T1 ATE413389 T1 AT E413389T1 AT 05701999 T AT05701999 T AT 05701999T AT 05701999 T AT05701999 T AT 05701999T AT E413389 T1 ATE413389 T1 AT E413389T1
Authority
AT
Austria
Prior art keywords
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
AT05701999T
Other languages
English (en)
Inventor
Benedicte Delouvrie
Craig Steven Harris
Laurent F A Hennequin
C T Halsall
Janet Elizabeth Pease
Peter Mark Smith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34833782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE413389(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE413389T1 publication Critical patent/ATE413389T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05701999T 2004-02-03 2005-01-31 Chinazolinderivate ATE413389T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04290274 2004-02-03

Publications (1)

Publication Number Publication Date
ATE413389T1 true ATE413389T1 (de) 2008-11-15

Family

ID=34833782

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05701999T ATE413389T1 (de) 2004-02-03 2005-01-31 Chinazolinderivate

Country Status (11)

Country Link
US (1) US7632840B2 (de)
EP (1) EP1713781B1 (de)
JP (1) JP5032851B2 (de)
CN (1) CN1914182B (de)
AR (1) AR047703A1 (de)
AT (1) ATE413389T1 (de)
DE (1) DE602005010824D1 (de)
ES (1) ES2315834T3 (de)
TW (1) TW200529851A (de)
UY (1) UY28736A1 (de)
WO (1) WO2005075439A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
EP1664028A1 (de) * 2003-09-16 2006-06-07 AstraZeneca AB Chinazolinderivate als tyrosinkinaseinhibitoren
EP1664030A1 (de) * 2003-09-16 2006-06-07 AstraZeneca AB Chinazolinderivate
AU2004272346A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
BRPI0511741A (pt) * 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
ATE501148T1 (de) * 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
ATE488513T1 (de) * 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
WO2007063293A1 (en) * 2005-12-02 2007-06-07 Astrazeneca Ab Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
EP1957499A1 (de) * 2005-12-02 2008-08-20 AstraZeneca AB 4-anilinosubstituierte chinazolinderivate als tyrosinkinaseinhibitoren
JP2010525069A (ja) 2007-04-27 2010-07-22 パラテック ファーマシューティカルズ インコーポレイテッド アミノアルキルテトラサイクリン化合物の合成方法および精製方法
BRPI0823405A2 (pt) * 2007-07-06 2012-12-25 Paratek Pharmaceuticals, Inc. mÉtodos para sintetizar compostos de tetraciclina substituÍda
US7662967B2 (en) 2007-08-02 2010-02-16 Cambridge Enterprise Limited Anti-inflammatory compounds and compositions
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
GB201604329D0 (en) * 2016-03-14 2016-04-27 Univ Strathclyde Methods and systems for improving stability of a ship
CN111777620A (zh) * 2019-04-04 2020-10-16 山东轩竹医药科技有限公司 酪氨酸激酶抑制剂的新用途

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
US4921863A (en) 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH11507329A (ja) 1995-04-27 1999-06-29 ゼネカ リミテッド キナゾリン誘導体
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (de) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazolinderivate
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU5195999A (en) 1998-08-11 2000-03-06 Takeda Chemical Industries Ltd. Cyclic amide compounds, process for producing the same, intermediates thereof and herbicides
IL142092A0 (en) 1998-09-29 2002-03-10 American Cyanamid Co Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
ATE232205T1 (de) 1998-10-01 2003-02-15 Astrazeneca Ab Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CA2361174C (en) 1999-02-27 2009-10-27 Boehringer Ingelheim Pharma Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
HK1044769B (zh) 1999-06-21 2005-02-25 贝林格尔英格海姆法玛两合公司 雙環雜環化合物，含有該化合物的藥物組合物，該化合物的用途及其製備方法
CN1360582A (zh) 1999-07-07 2002-07-24 阿斯特拉曾尼卡英国有限公司 喹唑啉衍生物
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2384291A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EP1292591B1 (de) 2000-06-22 2005-02-02 Pfizer Products Inc. Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
AU2002216758A1 (en) 2000-07-03 2002-01-14 Astrazeneca Ab Quinazolines with therapeutic use
EP1305308B1 (de) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung
DE10040527A1 (de) 2000-08-18 2002-02-28 Boehringer Ingelheim Pharma Chinazoline und Verfahren zu ihrer Herstellung
WO2002016352A1 (en) 2000-08-21 2002-02-28 Astrazeneca Ab Quinazoline derivatives
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20020082270A1 (en) 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
WO2002024684A1 (en) 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Quinoline derivatives as antibacterials
JP2004511479A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
AU2002212436A1 (en) 2000-10-25 2002-05-06 Astrazeneca Ab Quinazoline derivatives
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
ATE369894T1 (de) 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
WO2002062767A1 (en) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
CA2442742A1 (en) 2001-02-21 2002-08-29 Mitsubishi Pharma Corporation Quinazoline derivatives
PL364625A1 (en) 2001-02-23 2004-12-13 Merck & Co, Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
EP1396488A1 (de) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Kondensierte heterocyclische verbindung und deren medizinische verwendung
CA2349044A1 (en) 2001-05-28 2002-11-28 Optenia, Inc. Method of polarisation compensation in grating-and phasar-based devices by using overlayer deposited on the compensating region to modify local slab waveguide birefringence
US20050043336A1 (en) 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
AP2004003058A0 (en) 2001-12-12 2004-06-30 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth.
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP4776882B2 (ja) 2002-03-30 2011-09-21 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 二環式複素環化合物、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法
CA2514479A1 (en) 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
GB0309009D0 (en) 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
UY28441A1 (es) 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
AU2004272346A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
ATE395346T1 (de) 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
EP1664030A1 (de) 2003-09-16 2006-06-07 AstraZeneca AB Chinazolinderivate
EP1664028A1 (de) 2003-09-16 2006-06-07 AstraZeneca AB Chinazolinderivate als tyrosinkinaseinhibitoren
CN1882570B (zh) 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
WO2005030757A1 (en) 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
BRPI0511741A (pt) 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
ATE501148T1 (de) 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
KR20070107151A (ko) 2005-02-26 2007-11-06 아스트라제네카 아베 티로신 키나제 억제제로서의 퀴나졸린 유도체
GB0504474D0 (en) 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0504475D0 (en) 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
JP2009508917A (ja) 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
ATE488513T1 (de) 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
WO2007063293A1 (en) 2005-12-02 2007-06-07 Astrazeneca Ab Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
EP1957499A1 (de) 2005-12-02 2008-08-20 AstraZeneca AB 4-anilinosubstituierte chinazolinderivate als tyrosinkinaseinhibitoren

Also Published As

Publication number Publication date
CN1914182B (zh) 2011-09-07
US20070293490A1 (en) 2007-12-20
DE602005010824D1 (de) 2008-12-18
UY28736A1 (es) 2005-09-30
US7632840B2 (en) 2009-12-15
HK1095590A1 (en) 2007-05-11
EP1713781B1 (de) 2008-11-05
CN1914182A (zh) 2007-02-14
TW200529851A (en) 2005-09-16
EP1713781A1 (de) 2006-10-25
JP2007523072A (ja) 2007-08-16
JP5032851B2 (ja) 2012-09-26
WO2005075439A1 (en) 2005-08-18
AR047703A1 (es) 2006-02-08
ES2315834T3 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
CY2019034I2 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
ATE413389T1 (de) Chinazolinderivate
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
DE602004004553D1 (de) Chinazolinderivate
DE602004022180D1 (de) Chinazolinderivate
DK1725553T3 (da) Tetrahydropyridoindolderivater
ATE540935T1 (de) Chinazolinderivate
DK1809978T3 (da) Modul-skydebane
DK1761541T3 (da) Pyrrazolo-pyrimidin-derivater
DE112005001624A5 (de) Brillengestell
ATE512960T1 (de) Pyrimidinderivate
ATE417830T1 (de) Sulfonylbenzimidazolderivate
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
ATE392425T1 (de) Thiazolyl-dihydro-indazole
ATE459633T1 (de) Makrolide
DE112005000809A5 (de) Wankstabilisierungseinrichtung
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
DE202004017327U1 (de) Fitnessrad
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate
ATE365731T1 (de) 4-amino-5-cyanopyrimidinderivate
AT500198B1 (de) Ladewagen
DE112005000794T5 (de) Urethanspritzpistolenanordnung
ATE389633T1 (de) Omega-phenyloctanamide
EP1799223A4 (de) Arylthiobenzylpiperidin-derivate
DE502004001961D1 (de) Barikadenbrecher

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties